{"id":985757,"date":"2026-07-28T11:12:36","date_gmt":"2026-07-28T15:12:36","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/adma-august-10-2026-deadline-adma-biologics-inc-investors-have-opportunity-to-lead-class-action-lawsuit-hbss\/"},"modified":"2026-07-28T11:12:36","modified_gmt":"2026-07-28T15:12:36","slug":"adma-august-10-2026-deadline-adma-biologics-inc-investors-have-opportunity-to-lead-class-action-lawsuit-hbss","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/adma-august-10-2026-deadline-adma-biologics-inc-investors-have-opportunity-to-lead-class-action-lawsuit-hbss\/","title":{"rendered":"ADMA AUGUST 10, 2026 DEADLINE: ADMA Biologics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit- HBSS"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\">SAN FRANCISCO<\/span>, <span class=\"legendSpanClass\">July 28, 2026<\/span> \/PRNewswire\/ &#8212; Hagens Berman alerts investors in ADMA Biologics, Inc. <b>(NASDAQ: ADMA)<\/b>\u00a0that a securities <span>fraud<\/span> class action lawsuit has been filed. The lawsuit focuses on <span>alleged<\/span> misrepresentations concerning the company&#8217;s financial condition, revenue recognition, inventory distribution, and business practices.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <img decoding=\"async\" src=\"https:\/\/mmx.prnewswire.com\/media\/MS1117217\/Hagens-Berman-Sobol-Shapiro-LLP-Logo.jpg?id=OA2796787\" title=\"Class Action\" alt=\"Class Action\" \/>\n        <\/p>\n<\/p><\/div>\n<p class=\"prntac\">\n        <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4740080-1&amp;h=593274696&amp;u=https%3A%2F%2Fwww.hbsslaw.com%2Finvestor-fraud%2Fadma&amp;a=SUBMIT+YOUR+ADMA+LOSSES+TO+HAGENS+BERMAN+NOW\" target=\"_blank\" rel=\"nofollow\"><br \/>\n          <b>SUBMIT YOUR ADMA LOSSES TO HAGENS BERMAN NOW<\/b><br \/>\n        <\/a>\u00a0<\/p>\n<p>\n        <b>Key ADMA Class Action Details<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <b>Class Period: <\/b>Aug. 9, 2024 \u2013 Mar. 25, 2026<\/li>\n<li>\n          <b>Lead Plaintiff Deadline: <\/b>Aug. 10, 2026<\/li>\n<li>\n          <b>Visit:<\/b>\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4740080-1&amp;h=1586712692&amp;u=http%3A%2F%2Fwww.hbsslaw.com%2Finvestor-fraud%2Fadma&amp;a=www.hbsslaw.com%2Finvestor-fraud%2Fadma\" target=\"_blank\" rel=\"nofollow\">www.hbsslaw.com\/investor-<span>fraud<\/span>\/adma<\/a>\u00a0<\/li>\n<li>\n          <b>Contact the Firm Now:<\/b>\u00a0<a href=\"mailto:ADMA@hbsslaw.com\" target=\"_blank\" rel=\"nofollow\">ADMA@hbsslaw.com<\/a><br \/>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0<b>844-916-0895<\/b><\/li>\n<\/ul>\n<p>\n        <b><br \/>\n          <span>Alleged<\/span> Wrongdoing in ADMA Biologics Lawsuit: <\/b>\n      <\/p>\n<p>The lawsuit <span>alleges<\/span> that Defendants artificially inflated stock value by misrepresenting and failing to disclose that:<\/p>\n<ul type=\"disc\">\n<li>ADMA Biologics engaged in an undisclosed related party transaction;<\/li>\n<li>ADMA Biologics used channel stuffing to create an appearance of revenue;<\/li>\n<li>ADMA Biologics lacked adequate internal controls; and<\/li>\n<li>As a result, Defendants&#8217; statements about ADMA Biologics&#8217; business, operations, and prospects were materially false and misleading and\/or lacked a reasonable basis at all relevant times.<\/li>\n<\/ul>\n<p>\n        <b>The Truth Emerges and Market Reaction:<\/b>\n      <\/p>\n<p>The suit <span>alleges<\/span> that the misstatements were revealed through several corrective disclosure events, which wiped out substantial shareholder value, exposing investors to severe financial harm.<\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Date<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Corrective Event<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Stock Price Impact<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>March 24, 2026<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Culper Research publishes short-seller report revealing channel stuffing, rebates, and undisclosed related-party distributor Genesis BioPharma, triggering intense market sell-offs over two trading days as investors digest the revelations.<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>-31.6% combined<\/b><br \/>\n                <\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">(March 24: Down 16.6% to $11.33)<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">(March 25: Down 15.0% to $9.63)<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>March 26, 2026<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">ADMA issues a press release responding to the short-seller report stating it was &#8220;taking appropriate steps to review the assertions,&#8221; alongside a stock rating downgrade from Cantor Fitzgerald, further eroding investor confidence.<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>-13.9%<\/b><br \/>\n                <\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">(Down $1.34 to close at $8.29)<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n<p>\n        <b>Hagens Berman&#8217;s Investigation <\/b>\n      <\/p>\n<p>&#8220;We&#8217;re investigation whether ADMA made false and misleading statements to investors concealing the reality of its distribution channels and financial reporting, as the suit <span>alleges<\/span>&#8221; said <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4740080-1&amp;h=3636725565&amp;u=https%3A%2F%2Fwww.hbsslaw.com%2Fattorneys%2Freed-kathrein&amp;a=Reed+Kathrein\" target=\"_blank\" rel=\"nofollow\"><b>Reed Kathrein<\/b><\/a>, the Hagens Berman partner leading the firm&#8217;s investigation of the lawsuit&#8217;s claims.<\/p>\n<p>\n        <b>What Affected ADMA Investors Can Do<\/b>\n      <\/p>\n<p>If you invested in ADMA and have substantial losses, or have knowledge that may assist the firm&#8217;s investigation, <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4740080-1&amp;h=1622592189&amp;u=https%3A%2F%2Fwww.hbsslaw.com%2Finvestor-fraud%2Fadma&amp;a=submit+your+information+to+Hagens+Berman\" target=\"_blank\" rel=\"nofollow\"><b>submit your information to Hagens Berman<\/b><\/a>\u00a0\u00bb<\/p>\n<p>If you&#8217;d like more information and answers to frequently asked questions about the ADMA case and the firm&#8217;s investigation, <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4740080-1&amp;h=760149522&amp;u=https%3A%2F%2Fwww.hbsslaw.com%2Fcases%2Fadma-biologics-inc-adma-securities-class-action&amp;a=read+more%C2%A0%C2%BB\" target=\"_blank\" rel=\"nofollow\">read more\u00a0\u00bb<\/a><\/p>\n<p>\n        <b>Whistleblowers: <\/b>Persons with non-public information regarding ADMA should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at <b>844-916-0895<\/b>\u00a0or email <a href=\"mailto:ADMA@hbsslaw.com\" target=\"_blank\" rel=\"nofollow\">ADMA@hbsslaw.com<\/a>.<\/p>\n<p>\n        <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4740080-1&amp;h=1125545305&amp;u=https%3A%2F%2Fwww.hbsslaw.com%2F&amp;a=About+Hagens+Berman\" target=\"_blank\" rel=\"nofollow\">About Hagens Berman<\/a><br \/>\n        <br \/>Hagens Berman is a global plaintiffs&#8217; rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman&#8217;s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4740080-1&amp;h=2796460128&amp;u=https%3A%2F%2Fwww.hbsslaw.com%2F&amp;a=hbsslaw.com\" target=\"_blank\" rel=\"nofollow\">hbsslaw.com<\/a>. Follow the firm for updates and news at\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4740080-1&amp;h=2620610414&amp;u=https%3A%2F%2Fwww.twitter.com%2FClassActionLaw&amp;a=%40ClassActionLaw\" target=\"_blank\" rel=\"nofollow\">@ClassActionLaw<\/a>.\u00a0<\/p>\n<p>Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=SF13368&amp;sd=2026-07-28\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/adma-august-10-2026-deadline-adma-biologics-inc-investors-have-opportunity-to-lead-class-action-lawsuit-hbss-302836284.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/adma-august-10-2026-deadline-adma-biologics-inc-investors-have-opportunity-to-lead-class-action-lawsuit-hbss-302836284.html<\/a><\/p>\n<p>SOURCE Hagens Berman Sobol Shapiro LLP<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=SF13368&amp;Transmission_Id=202607281010PR_NEWS_USPR_____SF13368&amp;DateId=20260728\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire SAN FRANCISCO, July 28, 2026 \/PRNewswire\/ &#8212; Hagens Berman alerts investors in ADMA Biologics, Inc. (NASDAQ: ADMA)\u00a0that a securities fraud class action lawsuit has been filed. The lawsuit focuses on alleged misrepresentations concerning the company&#8217;s financial condition, revenue recognition, inventory distribution, and business practices. SUBMIT YOUR ADMA LOSSES TO HAGENS BERMAN NOW \u00a0 Key ADMA Class Action Details Class Period: Aug. 9, 2024 \u2013 Mar. 25, 2026 Lead Plaintiff Deadline: Aug. 10, 2026 Visit:\u00a0www.hbsslaw.com\/investor-fraud\/adma\u00a0 Contact the Firm Now:\u00a0ADMA@hbsslaw.com\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0844-916-0895 Alleged Wrongdoing in ADMA Biologics Lawsuit: The lawsuit alleges that Defendants artificially inflated stock value by misrepresenting and failing to disclose &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/adma-august-10-2026-deadline-adma-biologics-inc-investors-have-opportunity-to-lead-class-action-lawsuit-hbss\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ADMA AUGUST 10, 2026 DEADLINE: ADMA Biologics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit- HBSS&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-985757","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ADMA AUGUST 10, 2026 DEADLINE: ADMA Biologics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit- HBSS - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/adma-august-10-2026-deadline-adma-biologics-inc-investors-have-opportunity-to-lead-class-action-lawsuit-hbss\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ADMA AUGUST 10, 2026 DEADLINE: ADMA Biologics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit- HBSS - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN FRANCISCO, July 28, 2026 \/PRNewswire\/ &#8212; Hagens Berman alerts investors in ADMA Biologics, Inc. (NASDAQ: ADMA)\u00a0that a securities fraud class action lawsuit has been filed. The lawsuit focuses on alleged misrepresentations concerning the company&#8217;s financial condition, revenue recognition, inventory distribution, and business practices. SUBMIT YOUR ADMA LOSSES TO HAGENS BERMAN NOW \u00a0 Key ADMA Class Action Details Class Period: Aug. 9, 2024 \u2013 Mar. 25, 2026 Lead Plaintiff Deadline: Aug. 10, 2026 Visit:\u00a0www.hbsslaw.com\/investor-fraud\/adma\u00a0 Contact the Firm Now:\u00a0ADMA@hbsslaw.com\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0844-916-0895 Alleged Wrongdoing in ADMA Biologics Lawsuit: The lawsuit alleges that Defendants artificially inflated stock value by misrepresenting and failing to disclose &hellip; Continue reading &quot;ADMA AUGUST 10, 2026 DEADLINE: ADMA Biologics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit- HBSS&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/adma-august-10-2026-deadline-adma-biologics-inc-investors-have-opportunity-to-lead-class-action-lawsuit-hbss\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-28T15:12:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mmx.prnewswire.com\/media\/MS1117217\/Hagens-Berman-Sobol-Shapiro-LLP-Logo.jpg?id=OA2796787\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adma-august-10-2026-deadline-adma-biologics-inc-investors-have-opportunity-to-lead-class-action-lawsuit-hbss\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adma-august-10-2026-deadline-adma-biologics-inc-investors-have-opportunity-to-lead-class-action-lawsuit-hbss\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ADMA AUGUST 10, 2026 DEADLINE: ADMA Biologics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit- HBSS\",\"datePublished\":\"2026-07-28T15:12:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adma-august-10-2026-deadline-adma-biologics-inc-investors-have-opportunity-to-lead-class-action-lawsuit-hbss\\\/\"},\"wordCount\":560,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adma-august-10-2026-deadline-adma-biologics-inc-investors-have-opportunity-to-lead-class-action-lawsuit-hbss\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1117217\\\/Hagens-Berman-Sobol-Shapiro-LLP-Logo.jpg?id=OA2796787\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adma-august-10-2026-deadline-adma-biologics-inc-investors-have-opportunity-to-lead-class-action-lawsuit-hbss\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adma-august-10-2026-deadline-adma-biologics-inc-investors-have-opportunity-to-lead-class-action-lawsuit-hbss\\\/\",\"name\":\"ADMA AUGUST 10, 2026 DEADLINE: ADMA Biologics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit- HBSS - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adma-august-10-2026-deadline-adma-biologics-inc-investors-have-opportunity-to-lead-class-action-lawsuit-hbss\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adma-august-10-2026-deadline-adma-biologics-inc-investors-have-opportunity-to-lead-class-action-lawsuit-hbss\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1117217\\\/Hagens-Berman-Sobol-Shapiro-LLP-Logo.jpg?id=OA2796787\",\"datePublished\":\"2026-07-28T15:12:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adma-august-10-2026-deadline-adma-biologics-inc-investors-have-opportunity-to-lead-class-action-lawsuit-hbss\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adma-august-10-2026-deadline-adma-biologics-inc-investors-have-opportunity-to-lead-class-action-lawsuit-hbss\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adma-august-10-2026-deadline-adma-biologics-inc-investors-have-opportunity-to-lead-class-action-lawsuit-hbss\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1117217\\\/Hagens-Berman-Sobol-Shapiro-LLP-Logo.jpg?id=OA2796787\",\"contentUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1117217\\\/Hagens-Berman-Sobol-Shapiro-LLP-Logo.jpg?id=OA2796787\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adma-august-10-2026-deadline-adma-biologics-inc-investors-have-opportunity-to-lead-class-action-lawsuit-hbss\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ADMA AUGUST 10, 2026 DEADLINE: ADMA Biologics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit- HBSS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ADMA AUGUST 10, 2026 DEADLINE: ADMA Biologics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit- HBSS - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/adma-august-10-2026-deadline-adma-biologics-inc-investors-have-opportunity-to-lead-class-action-lawsuit-hbss\/","og_locale":"en_US","og_type":"article","og_title":"ADMA AUGUST 10, 2026 DEADLINE: ADMA Biologics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit- HBSS - Market Newsdesk","og_description":"PR Newswire SAN FRANCISCO, July 28, 2026 \/PRNewswire\/ &#8212; Hagens Berman alerts investors in ADMA Biologics, Inc. (NASDAQ: ADMA)\u00a0that a securities fraud class action lawsuit has been filed. The lawsuit focuses on alleged misrepresentations concerning the company&#8217;s financial condition, revenue recognition, inventory distribution, and business practices. SUBMIT YOUR ADMA LOSSES TO HAGENS BERMAN NOW \u00a0 Key ADMA Class Action Details Class Period: Aug. 9, 2024 \u2013 Mar. 25, 2026 Lead Plaintiff Deadline: Aug. 10, 2026 Visit:\u00a0www.hbsslaw.com\/investor-fraud\/adma\u00a0 Contact the Firm Now:\u00a0ADMA@hbsslaw.com\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0844-916-0895 Alleged Wrongdoing in ADMA Biologics Lawsuit: The lawsuit alleges that Defendants artificially inflated stock value by misrepresenting and failing to disclose &hellip; Continue reading \"ADMA AUGUST 10, 2026 DEADLINE: ADMA Biologics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit- HBSS\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/adma-august-10-2026-deadline-adma-biologics-inc-investors-have-opportunity-to-lead-class-action-lawsuit-hbss\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-28T15:12:36+00:00","og_image":[{"url":"https:\/\/mmx.prnewswire.com\/media\/MS1117217\/Hagens-Berman-Sobol-Shapiro-LLP-Logo.jpg?id=OA2796787","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adma-august-10-2026-deadline-adma-biologics-inc-investors-have-opportunity-to-lead-class-action-lawsuit-hbss\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adma-august-10-2026-deadline-adma-biologics-inc-investors-have-opportunity-to-lead-class-action-lawsuit-hbss\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ADMA AUGUST 10, 2026 DEADLINE: ADMA Biologics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit- HBSS","datePublished":"2026-07-28T15:12:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adma-august-10-2026-deadline-adma-biologics-inc-investors-have-opportunity-to-lead-class-action-lawsuit-hbss\/"},"wordCount":560,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adma-august-10-2026-deadline-adma-biologics-inc-investors-have-opportunity-to-lead-class-action-lawsuit-hbss\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1117217\/Hagens-Berman-Sobol-Shapiro-LLP-Logo.jpg?id=OA2796787","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adma-august-10-2026-deadline-adma-biologics-inc-investors-have-opportunity-to-lead-class-action-lawsuit-hbss\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/adma-august-10-2026-deadline-adma-biologics-inc-investors-have-opportunity-to-lead-class-action-lawsuit-hbss\/","name":"ADMA AUGUST 10, 2026 DEADLINE: ADMA Biologics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit- HBSS - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adma-august-10-2026-deadline-adma-biologics-inc-investors-have-opportunity-to-lead-class-action-lawsuit-hbss\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adma-august-10-2026-deadline-adma-biologics-inc-investors-have-opportunity-to-lead-class-action-lawsuit-hbss\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1117217\/Hagens-Berman-Sobol-Shapiro-LLP-Logo.jpg?id=OA2796787","datePublished":"2026-07-28T15:12:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adma-august-10-2026-deadline-adma-biologics-inc-investors-have-opportunity-to-lead-class-action-lawsuit-hbss\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/adma-august-10-2026-deadline-adma-biologics-inc-investors-have-opportunity-to-lead-class-action-lawsuit-hbss\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adma-august-10-2026-deadline-adma-biologics-inc-investors-have-opportunity-to-lead-class-action-lawsuit-hbss\/#primaryimage","url":"https:\/\/mmx.prnewswire.com\/media\/MS1117217\/Hagens-Berman-Sobol-Shapiro-LLP-Logo.jpg?id=OA2796787","contentUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1117217\/Hagens-Berman-Sobol-Shapiro-LLP-Logo.jpg?id=OA2796787"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adma-august-10-2026-deadline-adma-biologics-inc-investors-have-opportunity-to-lead-class-action-lawsuit-hbss\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ADMA AUGUST 10, 2026 DEADLINE: ADMA Biologics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit- HBSS"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/985757","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=985757"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/985757\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=985757"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=985757"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=985757"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}